SCHEMBL25364331

SCHEMBL25364331

N#CNC(=N)c1csc(CN)c1

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25363779 0.81 RAB9A (0.39) DAO
SCHEMBL29035112 0.80 DAO (0.34) DAO
Hydrochloric Acid SCHEMBL25364781 0.78 DAO (0.33) DAO
SCHEMBL25362626 0.78 DAO (0.36) DAO
SCHEMBL25364950 0.74 DAO (0.41) DAO
SCHEMBL1738243 0.73 F10 (0.42) DAO
Hydrochloric Acid SCHEMBL25365653 0.73 DAO (0.37) DAO
SCHEMBL25363448 0.73 LOX (0.35) DAO
SCHEMBL25364110 0.72 DAO (0.39) DAO
Hydrochloric Acid SCHEMBL25364185 0.72 LOX (0.34) DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed
WO-2022066774-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2022-03-31 WO disclosed